ENTX Key Statistics, Chart & Performance
The current stock price of ENTX is 1.4 USD. In the past month the price decreased by -27%. In the past year, price decreased by -33.33%.
ENTX Technical Analysis
ENTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ENTX. No worries on liquidiy or solvency for ENTX as it has an excellent financial health rating, but there are worries on the profitability.
ENTX Financial Highlights
Over the last trailing twelve months ENTX reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS increased by 50% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.93% | ||
| ROE | -70.77% | ||
| Debt/Equity | 0 |
ENTX Forecast & Estimates
7 analysts have analysed ENTX and the average price target is 10.2 USD. This implies a price increase of 628.57% is expected in the next year compared to the current price of 1.4.
For the next year, analysts expect an EPS growth of -14.24% and a revenue growth -69.78% for ENTX
ENTX Ownership
About ENTX
Company Profile
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Company Info
ENTERA BIO LTD
Hadassah / Jerusalem Bio, Park, 5th Floor
JERUSALEM 9112002 IL
CEO: Spiros Jamas
Employees: 20
Phone: 97225327151
ENTERA BIO LTD / ENTX FAQ
What does ENTX do?
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Can you provide the latest stock price for ENTERA BIO LTD?
The current stock price of ENTX is 1.4 USD. The price decreased by -4.11% in the last trading session.
Does ENTERA BIO LTD pay dividends?
ENTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ENTX stock?
ENTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of ENTERA BIO LTD (ENTX)?
ENTERA BIO LTD (ENTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).
What is the market capitalization of ENTX stock?
ENTERA BIO LTD (ENTX) has a market capitalization of 64.20M USD. This makes ENTX a Micro Cap stock.
What is the next earnings date for ENTX stock?
ENTERA BIO LTD (ENTX) will report earnings on 2026-03-26, after the market close.